Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update

Theratechnologies Inc. (NASDAQ:THTX) was the recipient of a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 43,000 shares, a growth of 26.8% from the October 15th total of 33,900 shares. Based on an average trading volume of 33,400 shares, the short-interest ratio is presently 1.3 days. Currently, 0.2% of the company’s shares are sold short.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Theratechnologies stock. Cyndeo Wealth Partners LLC lifted its position in shares of Theratechnologies Inc. (NASDAQ:THTX) by 26.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 131,311 shares of the company’s stock after purchasing an additional 27,191 shares during the quarter. Cyndeo Wealth Partners LLC owned 0.29% of Theratechnologies worth $163,000 at the end of the most recent reporting period.

Theratechnologies Stock Down 2.5 %

THTX stock opened at $1.18 on Friday. Theratechnologies has a twelve month low of $1.08 and a twelve month high of $2.58. The company has a market cap of $54.26 million, a P/E ratio of -11.80 and a beta of 1.41. The business’s fifty day moving average is $1.25 and its 200-day moving average is $1.31.

Theratechnologies (NASDAQ:THTX) last released its earnings results on Thursday, October 10th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03. The company had revenue of $22.60 million during the quarter. During the same quarter last year, the firm earned ($0.03) earnings per share. Research analysts anticipate that Theratechnologies will post 0.03 earnings per share for the current fiscal year.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.